



Company Overview

Humanigen, Inc. is a biopharmaceutical company developing cutting-edge CAR-T optimization and oncology treatments. Derived from the company's Humaneered® platform, lenzilumab, ifabotuzumab and HGEN005 are monoclonal antibodies with first-in-class mechanisms. Lenzilumab, which targets GM-CSF, is in development as a potential medicine to make CAR-T therapy safer and more effective, as well as a potential treatment for rare hematologic cancers such as CMML and JMML. Ifabotuzumab, which targets Eph receptor A3 (EphA3), is being explored as a potential treatment for glioblastoma multiforme (GBM) and other deadly cancers, as well as a backbone for a novel CAR-T construct and bispecific antibody platform. HGEN005, which targets human epidermal growth factor-like module containing mucin-like hormone receptor 1 (EMR1), has potential as a treatment for eosinophilic diseases, such as a novel CAR-T construct for eosinophilic leukemia.

Humanigen, Inc.

1000 Marina Boulevard
Suite 250
Brisbane, CA 94005

Humanigen CEO to Present at 8th Annual LD Micro Invitational

May 30 2018, 8:00 AM EDT

Humanigen Announces Preclinical Findings Presented on Lenzilumab's Potential to Optimize CAR-T Therapy

May 2 2018, 4:10 PM EDT

Humanigen Names Dr. Tarek Sahmoud as Chief Medical Officer

Apr 30 2018, 7:00 AM EDT

Stock Overview

Symbol	HGEN
Exchange	OTCQB
Shares OS	109,207,786
Market Cap	\$67.69M
Last Price	\$0.6198
52-Week Range	\$0.125 - \$2.60

Investor Relations

Al Palombo
T: 650-243-3181
ir@humanigen.com

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.